The AT&T case is a good reminder that there are risks associated with selective disclosure of material information.
In calls and emails, TherapeuticsMD shared material, nonpublic information about a new drug's likelihood of FDA approval with sell-side analysts.
Francesca’s Collections says it didn’t know its now-fired finance chief had tipped off investors to an upcoming positive earnings report. The SEC may come calling anyway.
